Suven Life Sciences announced its un-audited financial results for the quarter and year ended June 30, 2014. During the first quarter ended June 2014, the growth in revenue is Rs 1426 million, growth in PAT is Rs 347 million and growth in EBIDTA is Rs 590 million.
Suven’s major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 89 million (6.28 per cent on revenue) for the quarter ended June 2014.
EP News Bureau- Mumbai
